Logitech International: Logitech Files Annual Report on Form 10-K
Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced that it filed its Annual Report on Form 10-K for Fiscal Year 2021 with the U.S. Securities and Exchange Commission (SEC). The filing is available on the SEC s website at www.sec.gov and Logitech s website at http://ir.logitech.com. Logitech expects to publish its annual report to shareholders, and its invitation and proxy statement for its 2021 annual general meeting, in July 2021.
About Logitech
Logitech designs products that have an everyday place in people s lives, connecting them to the digital experiences they care about. Almost 40 years ago, Logitech started connecting people through computers, and now it s a multi-brand company designing products that bring people together through music, gaming, video, and computing. Brands of Logitech include Logitech, Logitech G, ASTRO Gaming, Streamlabs, Blue Microphones, Ultimate Ears and Jaybird. Founded
SECOND FISCAL QUARTER DETAILS
For the second quarter of fiscal 2021, Coherent announced net sales of $374.0 million and net loss, on a U.S. generally accepted accounting principles (GAAP) basis, of $158.2 million, or $6.49 per diluted share. The net loss includes $179.2 million, net of tax, in merger and acquisition costs, primarily due to a merger agreement termination fee paid to Lumentum Holdings Inc.
These results compare to net sales of $293.1 million and net loss of $418.9 million, or $17.39 per diluted share, for the second quarter of fiscal 2020 and net sales of $326.1 million and net income of $0.1 million, or $0.01 per diluted share, for the first quarter of fiscal 2021. The net loss for the second quarter of fiscal 2020 includes $424.3 million, net of tax, in non-cash goodwill and other impairment charges, primarily related to the impairment of all goodwill and certain long-lived assets in the Industrial Lasers & Systems segment of our business.
Regulatory News:
NANOBIOTIX (Euronext : NANO â NASDAQ: NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a partnership with LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and major Asian markets, to develop and commercialize Nanobiotix lead product candidate NBTXR3, a potential first-in-class radioenhancer, in Greater China (mainland China, Hong Kong, Taiwan, and Macau), South Korea, Singapore and Thailand.
Shanghai and Princeton-based LianBio was founded by Perceptive Advisors with an innovative partnership model to develop and commercialize therapeutics in China and other Asian markets. LianBioâs cross-border development and commercialization expertise includes strong capabilities in oncology and NBTXR3 is the third investigational cancer treatment in the companyâs portfolio. Given the global hi
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva Announces Closing of $107.6 million Global Offering
VALNEVAMay 11, 2021 GMT
Saint-Herblain (France), May 11, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced the closing which occurred on May 10, 2021 of its previously announced global offering to specified categories of investors of an aggregate of 8,145,176 new ordinary shares, after full exercise of the overallotment option granted to the underwriters (the “Option”), consisting of a public offering of 2,850,088 American Depositary Shares (“ADSs”), each representing two ordinary shares, in the United States at an offering price of $26.41 per ADS (the “U.S. Offering”), and a concurrent private placement of 2,445,000 ordinary shares in Europe (including in France) an
Citi Appointed as Depositary Bank for Valneva SE s ADR Programme
Citi, acting through Citibank N.A., has been appointed by Valneva SE ( Valneva ), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, to act as depositary bank for its American Depositary Receipt ( ADR ) programme.
Valneva s American Depositary Shares ( ADS ) trade on the Nasdaq Global Select Market under the symbol VALN . Each ADS represents two ordinary shares of the company. Valneva s underlying ordinary shares are listed and trade on Euronext Paris under the symbol VLA .
David Lawrence, Acting CFO of Valneva, said: We are pleased to be working with Citi as part of our team supporting our newly acquired Nasdaq listing.